China Construction Bank Corporation (601939.SS) vs Merck & Co., Inc. (MRK)

China Construction Bank Corporation is one of China’s largest commercial banks, with a strong position in infrastructure finance, mortgages, corporate banking, deposits, payments, and wealth management. The bank serves households, government-linked entities, property developers, industrial companies, and small businesses. Its performance is shaped by Chinese loan demand, interest margins, deposit growth, asset quality, and public policy. Because of its scale, it is closely connected to China’s broader credit cycle and domestic economic conditions.

Merck & Co., Inc. develops pharmaceutical products across multiple therapeutic areas, including cardiometabolic disorders, oncology, and infectious diseases. In cancer treatment, its immuno-oncology portfolio, led by Keytruda, represents a significant driver of total revenue. The company also maintains a strong vaccines business focused on preventing pediatric illnesses, alongside Gardasil for human papillomavirus. In addition, Merck markets animal health products. Geographically, 47% of the company’s sales come from its U.S. human health segment, which includes pharmaceuticals and vaccines.